Komipharm International Co. Ltd
Komipharm International Co., Ltd. manufactures and sells veterinary vaccines, veterinary pharmaceuticals and disinfectants, and bio-fertilizers internationally. It also develops anticancer drugs and pain-relieving agents, which include Kominox, an arsenic-based oral drug; and Panaphix, a non-narcotic cancer pain reliever, as well as provides clinical pathological experiment, test, and analysis se… Read more
Komipharm International Co. Ltd (041960) - Net Assets
Latest net assets as of September 2025: ₩74.86 Billion KRW
Based on the latest financial reports, Komipharm International Co. Ltd (041960) has net assets worth ₩74.86 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩133.65 Billion) and total liabilities (₩58.79 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩74.86 Billion |
| % of Total Assets | 56.01% |
| Annual Growth Rate | 4.02% |
| 5-Year Change | -14.08% |
| 10-Year Change | -13.91% |
| Growth Volatility | 16.24 |
Komipharm International Co. Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Komipharm International Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Komipharm International Co. Ltd (2011–2024)
The table below shows the annual net assets of Komipharm International Co. Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩65.54 Billion | +9.20% |
| 2023-12-31 | ₩60.02 Billion | -1.02% |
| 2022-12-31 | ₩60.63 Billion | -8.77% |
| 2021-12-31 | ₩66.46 Billion | -12.87% |
| 2020-12-31 | ₩76.28 Billion | +4.09% |
| 2019-12-31 | ₩73.28 Billion | -21.54% |
| 2018-12-31 | ₩93.39 Billion | -7.78% |
| 2017-12-31 | ₩101.27 Billion | +8.65% |
| 2016-12-31 | ₩93.20 Billion | +22.43% |
| 2015-12-31 | ₩76.13 Billion | +43.21% |
| 2014-12-31 | ₩53.16 Billion | +18.87% |
| 2013-12-31 | ₩44.72 Billion | +10.24% |
| 2012-12-31 | ₩40.56 Billion | +3.38% |
| 2011-12-31 | ₩39.24 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Komipharm International Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2576.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩72.95 Billion | 117.13% |
| Total Equity | ₩62.28 Billion | 100.00% |
Komipharm International Co. Ltd Competitors by Market Cap
The table below lists competitors of Komipharm International Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zoneco Group Co Ltd
SHE:002069
|
$237.31 Million |
|
Great Giant Fibre Garment Co., Ltd.
TWO:4441
|
$237.35 Million |
|
EZTEC Empreendimentos e Participações S.A
SA:EZTC3
|
$237.39 Million |
|
Investar Holding Corp
NASDAQ:ISTR
|
$237.39 Million |
|
Comp SA
WAR:CMP
|
$237.24 Million |
|
Skyworth Group Limited
PINK:SWDHF
|
$237.22 Million |
|
Shanghai Weihong Electronic Technology Co Ltd
SHE:300508
|
$237.20 Million |
|
Odfjell SE
OL:ODF
|
$237.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Komipharm International Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 56,337,796,060 to 62,280,266,440, a change of 5,942,470,380 (10.5%).
- Net income of 13,113,267,440 contributed positively to equity growth.
- Share repurchases of 3,678,487,340 reduced equity.
- Other factors decreased equity by 3,492,309,720.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩13.11 Billion | +21.06% |
| Share Repurchases | ₩3.68 Billion | -5.91% |
| Other Changes | ₩-3.49 Billion | -5.61% |
| Total Change | ₩- | 10.55% |
Book Value vs Market Value Analysis
This analysis compares Komipharm International Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.05x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 5.49x to 9.05x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1482.79 | ₩8140.00 | x |
| 2017-12-31 | ₩1599.65 | ₩8140.00 | x |
| 2018-12-31 | ₩1468.76 | ₩8140.00 | x |
| 2019-12-31 | ₩1151.66 | ₩8140.00 | x |
| 2020-12-31 | ₩1193.90 | ₩8140.00 | x |
| 2021-12-31 | ₩945.11 | ₩8140.00 | x |
| 2022-12-31 | ₩864.12 | ₩8140.00 | x |
| 2023-12-31 | ₩803.07 | ₩8140.00 | x |
| 2024-12-31 | ₩898.99 | ₩8140.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Komipharm International Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.06%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.31%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.97x
- Recent ROE (21.06%) is above the historical average (-5.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 2.49% | 4.57% | 0.29x | 1.90x | ₩-3.05 Billion |
| 2014 | -4.04% | -6.24% | 0.28x | 2.34x | ₩-7.47 Billion |
| 2015 | -8.60% | -17.99% | 0.27x | 1.75x | ₩-14.16 Billion |
| 2016 | 0.31% | 0.77% | 0.25x | 1.61x | ₩-9.03 Billion |
| 2017 | -5.03% | -13.91% | 0.25x | 1.47x | ₩-15.22 Billion |
| 2018 | -15.32% | -40.87% | 0.25x | 1.50x | ₩-23.64 Billion |
| 2019 | -29.15% | -60.20% | 0.28x | 1.71x | ₩-28.69 Billion |
| 2020 | -3.69% | -7.58% | 0.30x | 1.60x | ₩-10.44 Billion |
| 2021 | -6.71% | -12.44% | 0.31x | 1.73x | ₩-11.11 Billion |
| 2022 | -10.74% | -16.37% | 0.36x | 1.84x | ₩-12.58 Billion |
| 2023 | -7.06% | -9.33% | 0.36x | 2.11x | ₩-9.61 Billion |
| 2024 | 21.06% | 22.31% | 0.48x | 1.97x | ₩6.89 Billion |
Industry Comparison
This section compares Komipharm International Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $96,508,506,416
- Average return on equity (ROE) among peers: -8.88%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Komipharm International Co. Ltd (041960) | ₩74.86 Billion | 2.49% | 0.79x | $237.27 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $94.65 Billion | 9.66% | 0.53x | $57.77 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $890.75 Million |
| EstechPharma Co. Ltd (041910) | $123.30 Billion | 5.58% | 0.09x | $50.99 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $40.83 Billion | 8.91% | 0.29x | $20.48 Million |